North America Spinal Cord Stimulation Devices Market Outlook: Size, Share, Trends, Growth Analysis, Competitive Landscape & Forecast, 2026-2033

Rising chronic pain prevalence

The growth of the market for Spinal Cord Stimulation devices in North America will be fueled by the growing prevalence of disorders characterized by chronic pain syndromes such as neuropathic pain, failed back syndrome, and complex regional pain syndrome. The number of people who suffer from pain-related disorders is very high among the population living within the continent with figures pointing at more than 100 million people experiencing such pain conditions.

In the context of well-developed healthcare infrastructure, hospitals and SCS pain management clinics have been noting a consistent increase in the number of SCS implantation surgeries, which is attributed to more spinal surgeries and age-related disorders. Major hospital chains in large cities have reported an increase in the number of admissions of patients suffering from chronic pain in their limbs or backs, which may be associated with spinal degeneration due to poor life practices and post-operation problems.

Moreover, there has been a transition from the widespread use of opioids for pain management; hence, SCS implantation is gaining popularity. The growing recommendation of using SCS for patients experiencing intractable pain by regulatory authorities and medical associations is among the reasons for this trend.

Emerging market healthcare expansion

North American SCS devices are also witnessing the positive impact of ongoing growth in the health care sector and increased access to modern neuromodulation treatments. North America has one of the most developed hospital networks and high health care expenditure that has helped it adopt innovative techniques quickly in pain management therapies. Over the past few years, substantial investment made in the establishment of ambulatory surgery centers and pain clinics has widened the reach of SCS devices across hospitals.

Coverage and payment mechanisms are key factors in driving market growth. A considerable share of the spinal cord stimulator procedure is covered by public and private health insurance providers. This trend has been a source of reduced cost burden for patients, making them avail such expensive treatment options more frequently than before.

The rapid progress in technology along with the presence of prominent medical devices companies has contributed to growth. Innovations in the area of recharging systems, minimally invasive surgeries, and remote programmable systems have increased operational efficiencies. As health care organizations look at effective ways of managing pain in the long term, SCS devices are becoming an integral part of treatment processes.

The "North America Spinal Cord Stimulation Devices Market Size and Forecast (2022-2033)" report provides a detailed analysis of the market covering below areas:

• Market size and forecast at regional and country levels for all market segments covered under the scope
• Market trends, as well as drivers, restraints, and opportunities
• Market analysis covering key trends, regional framework, major players, regulations, and recent developments
• Market concentration, heat map analysis, prominent players, and recent developments for the Market
• Detailed company profiles, including SWOT analysis

The geographical scope of the North America spinal cord stimulation devices market report is divided into: The US, Canada, and Mexico. The US held the largest share in 2025.

The North American region is considered to be the most developed and technologically advanced spinal cord stimulators market. This region is dominated by the United States, due to its strong clinical expertise in the application of neurostimulation implants and the existence of a well-developed infrastructure related to the use of device-based pain management. Moreover, North America has many specialized clinics and medical centers that focus on chronic pain treatment and pain management. Such features provide an excellent environment for the implementation of new techniques in chronic pain management. Clinicians in North America apply neuromodulation early in their algorithm of treatment, mainly in the cases when the conventional treatments, such as conservative therapies and repeated surgeries, prove to be ineffective for the treatment of pain. Furthermore, the US enjoys strong collaboration between doctors and developers of spinal cord stimulation devices, leading to a rapid introduction of novel techniques and innovations. One of the main drivers contributing to the demand is the increasing focus on minimizing the reliance on opioids for treating chronic pain. As a result, there has been an increase in referrals for the use of spinal cord stimulation devices. Additionally, patients in the United States have become more open to interventional approaches, especially if recommended by pain management experts as part of multidisciplinary teams. Although the region is at the forefront of adoption, several factors may hinder its growth. For example, higher initial costs and complicated reimbursement models may affect how accessible it is to certain patients. Furthermore, prior authorization requirements and differences among insurance companies may impact the rate at which new generations of devices are adopted. However, with the integration of technology and clinical expertise, North America, dominated by the United States, will continue to be at the forefront of using spinal cord stimulation devices.

• The report includes qualitative and quantitative data in the North America spinal cord stimulation devices market across product type, type, application, end user, and geography.
• The report starts with the key takeaways (chapter 2), highlighting the key trends and outlook of the North America spinal cord stimulation devices market.
• Chapter 3 focuses on the research methodology of the study.
• Chapter 4 includes ecosystem analysis.
• Chapter 5 highlights the major industry dynamics in the North America spinal cord stimulation devices market, including factors that are driving the market, prevailing deterrents, potential opportunities, as well as future trends. Impact analysis of these drivers and restraints is also covered in this section.
• Chapter 6 discusses the North America spinal cord stimulation devices market scenario, in terms of historical market revenues, and forecast till the year 2033.
• Chapters 7 to 11 cover North America spinal cord stimulation devices market segments by product type, type, application, end user, and geography across the US, Canada, and Mexico. They cover the market revenue, forecast, and factors driving the market.
• Chapter 12 describes the competitive analysis along with the heat map analysis for the key players operating in the market.
• Chapter 13 describes the industry landscape analysis. It provides detailed descriptions of business activities such as market initiatives, new developments, mergers, and joint ventures globally, along with a competitive landscape.
• Chapter 14 provides detailed profiles of the major companies operating in the North America spinal cord stimulation devices market. Companies have been profiled on the basis of their key facts, business descriptions, products, financial overview, SWOT analysis, and key developments.
• Chapter 15, i.e., the appendix, is inclusive of a brief overview of the company, list of abbreviations, and disclaimer.

The North America spinal cord stimulation devices market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the key developments in the North America Spinal cord stimulation devices market are:

• In October 2025, Boston Scientific announced that it agreed to acquire the remaining equity in Nalu Medical to strengthen its neuromodulation and chronic pain portfolio, expanding its spinal cord stimulation and peripheral nerve stimulation offerings in the North American market.
• In May 2024, Medtronic announced that it received FDA approval for its Intellis™ Plus spinal cord stimulation system, featuring AI-based AdaptiveStim technology that automatically adjusts stimulation based on patient posture and activity to deliver more personalized chronic pain therapy across the U.S. market.